TG Therapeutics CEO to Present at H.C. Wainwright Conference
Event summary
- TG Therapeutics CEO Michael S. Weiss to participate in H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026.
- Fireside chat scheduled for 12:00pm ET, available via live webcast on the company's investor relations page.
- TG Therapeutics markets BRIUMVI® (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS) in the U.S. and internationally.
The big picture
TG Therapeutics' participation in the H.C. Wainwright conference underscores its push to solidify its position in the B-cell disease treatment market. With BRIUMVI already approved in the U.S. and several international markets, the company is likely to use this platform to discuss its commercialization strategy and pipeline advancements. The event comes at a critical time as the biotech sector continues to focus on novel treatments for autoimmune diseases.
What we're watching
- Commercial Execution
- How TG Therapeutics will leverage the conference to highlight BRIUMVI's market potential and expansion strategies.
- Regulatory Dynamics
- Whether the FDA's approval of BRIUMVI will drive further international regulatory successes.
- Investor Sentiment
- The pace at which investor confidence in TG Therapeutics' pipeline and commercialization efforts will grow.
Related topics